Keywords: Sanofi, Semuloparin, Zaltrap, DVT, Colorectal cancer, Regeneron Pharma

Sanofi presents benefits of semuloparin; Zaltrap improves colorectal cancer survival

Article | 07 June 2011

Print This

French drug major Sanofi (Euronext: SAN) announced results at the American Society of Clinical Oncology (ASCO) meeting in Chicago of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in